Abstract:A machine learning‐derived LCDS using peripheral blood transcriptomics enables early detection of lung cancer with high accuracy. Lower LCDS correlates with enhanced antitumor immunity, while higher LCDS associates with protumorigenic pathway activation. LCDS shows potential as a noninvasive biomarker for lung cancer screening and prognosis. Lung cancer continues to be the leading cause of cancer‐related mortality worldwide. Early detection and a comprehensive understanding of tumor‐immune interactions are crucial for improving patient outcomes. This study aimed to develop a novel biomarker panel utilizing peripheral blood transcriptomics and machine learning algorithms for early lung cancer diagnosis, while simultaneously providing insights into tumor‐immune crosstalk mechanisms. Leveraging a training cohort (GSE135304), we employed multiple machine learning algorithms to formulate a Lung Cancer Diagnostic Score (LCDS) based on peripheral blood transcriptomic features. The LCDS model's performance was evaluated using the area under the receiver operating characteristic (ROC) curve (AUC) in multiple validation cohorts (GSE42834, GSE157086, and an in‐house dataset). Peripheral blood samples were obtained from 20 lung cancer patients and 10 healthy control subjects, representing an in‐house cohort recruited at the Sixth People's Hospital of Chengdu. We employed advanced bioinformatics techniques to explore tumor‐immune interactions through comprehensive immune infiltration and pathway enrichment analyses. Initial screening identified 844 differentially expressed genes, which were subsequently refined to 87 genes using the Boruta feature selection algorithm. The random forest (RF) algorithm demonstrated the highest accuracy in constructing the LCDS model, yielding a mean AUC of 0.938. Lower LCDS values were significantly associated with elevated immune scores and increased CD4+ and CD8+ T‐cell infiltration, indicative of enhanced antitumor‐immune responses. Higher LCDS scores correlated with activation of hypoxia, peroxisome proliferator‐activated receptor (PPAR), and Toll‐like receptor (TLR) signaling pathways, as well as reduced DNA damage repair pathway scores. Our study presents a novel, machine learning‐derived peripheral blood transcriptomic biomarker panel with potential applications in early lung cancer diagnosis. The LCDS model not only demonstrates high accuracy in distinguishing lung cancer patients from healthy individuals but also offers valuable insights into tumor‐immune interactions and underlying cancer biology. This approach may facilitate early lung cancer detection and contribute to a deeper understanding of the molecular and cellular mechanisms underlying tumor‐immune crosstalk. Furthermore, our findings on the relationship between LCDS and immune infiltration patterns may have implications for future research on therapeutic strategies targeting the immune system in lung cancer.

Machine learning of serum metabolic patterns encodes early-stage lung adenocarcinoma

[Use of Laser Capture Microdissection and Surface-Enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Differential Proteins in Lung Adenocarcinoma and Lung Squamous Carcinoma].

Early lung cancer diagnostic biomarker discovery by machine learning methods

Integrative Serum Metabolic Fingerprints Based Multi‐Modal Platforms for Lung Adenocarcinoma Early Detection and Pulmonary Nodule Classification

Diagnosing lung cancer through metabolic fingerprint based on machine learning

High-resolution metabolomic biomarkers for lung cancer diagnosis and prognosis

Application of Laser Capture Microdissection and Surface-enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Biomarkers for Early Diagnosis of Lung Adenocarcinoma

Serum Untargeted Metabolomics Reveal Metabolic Alteration of Non‐small Cell Lung Cancer and Refine Disease Detection

Clinical Validation of Metabolite Markers for Early Lung Cancer Detection

Machine Learning for Early Discrimination Between Lung Cancer and Benign Nodules Using Routine Clinical and Laboratory Data

Serum Untargeted Metabolomics Analyses Reveal Metabolic Alteration of Non-Small Cell Lung Cancer and Refine Cancer Detection in Chinese Population

Development of a novel blood-based RNA gene expression platform for early-stage lung cancer diagnosis.

Machine learning‐derived peripheral blood transcriptomic biomarkers for early lung cancer diagnosis: Unveiling tumor‐immune interaction mechanisms

High-Throughput Salivary Metabolite Profiling on an Ultralow Noise Tip-Enhanced Laser Desorption Ionization Mass Spectrometry Platform for Noninvasive Diagnosis of Early Lung Cancer.

Biomarker Discovery and Identification from Non-Small Cell Lung Cancer Sera.

Combining MALDI-MS with machine learning for metabolomic characterization of lung cancer patient sera

A Peripheral Blood Transcriptomic Biomarker Panel Identified by Multiple Machine Learning Algorithms Enables Early Diagnosis and Prognosis Prediction in Lung Cancer

Label-free surface-enhanced Raman spectroscopy of serum based on multivariate statistical analysis for the diagnosis and staging of lung adenocarcinoma

Development Of Proteomic Patterns For Detecting Lung Cancer

Early Cancer Detection by Serum Biomolecular Fingerprinting Spectroscopy with Machine Learning

Machine learning-based proteogenomic data modeling identifies circulating plasma biomarkers for early detection of lung cancer